119TiP A multicenter, open-label, single-arm, non-interventional real-world study to investigate the treatment patterns of neratinib in HER2-positive early breast cancer (EBC) in China: NER-Tree study

X Wang,F Ling,J Gao,J Ye,A Zhang,S Zhang,Y Zhang,Y Wang,J Wu,X Liu,H Zhen,J Zhang

doi:10.1016/j.esmoop.2023.101343

119TiP A multicenter, open-label, single-arm, non-interventional real-world study to investigate the treatment patterns of neratinib in HER2-positive early breast cancer (EBC) in China: NER-Tree study

X Wang, F Ling + Show 10 more

Open Access

https://doi.org/10.1016/j.esmoop.2023.101343

Copy DOI

Journal: ESMO Open	Publication Date: May 1, 2023
License type: cc-by-nc-nd

Affiliation: Zhejiang Cancer Hospital, Cancer Hospital of Chinese Academy of Medical Sciences, The First People's Hospital of Zhaoqing, Maternal and Child Health Care Hospital of Bao'an, Xi'an Jiaotong University, Guangdong Medical College, Shandong Tumor Hospital, Cancer Hospital of Shantou University Medical College, Ningxia Medical University, Tianjin Medical University Cancer Institute and Hospital

#HER2-positive Early Breast Cancer #Early Breast Cancer + Show 5 more

Abstract
Full-Text PDF
Similar Papers

Abstract

119TiP A multicenter, open-label, single-arm, non-interventional real-world study to investigate the treatment patterns of neratinib in HER2-positive early breast cancer (EBC) in China: NER-Tree study

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: ESMO Open

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.